Imunon | 8-K: FY2025 Q3 Revenue: USD 0

LB filings

2025.11.13 12:50

I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -1.16, beating the estimate of USD -1.8052.

EBIT: As of FY2025 Q3, the actual value is USD -3.523 M.

Net Loss: The net loss for the third quarter of 2025 was $3.4 million, or $1.16 per share, compared to a net loss of $4.8 million, or $3.76 per share, for the third quarter of 2024.
Operating Expenses: Operating expenses were $3.5 million, a decrease of $1.5 million or 30% from $5.0 million for the third quarter of 2024.
R&D Expenses: Research and development expenses were $1.9 million, a decrease of $1.4 million from $3.3 million for the third quarter of 2024.
G&A Expenses: General and administrative expenses were $1.6 million, compared with $1.7 million for the third quarter of 2024.
Investment Income: Investment income from short-term investments was $47,000 for the third quarter of 2025 compared to $116,000 for the same period in 2024.

Net Loss: For the nine months ended September 30, 2025, the net loss was $10.3 million, or $5.53 per share, compared with a net loss of $14.6 million, or $14.13 per share, for the same period in 2024.
Operating Expenses: Operating expenses were $10.4 million, a decrease of $4.6 million or 31% from $15.0 million for the same period in 2024.
Net Cash Used: Net cash used for operating activities was $10.2 million for the first nine months of 2025, compared with $14.4 million for the same period in 2024.
R&D Expenses: R&D expenses were $5.3 million, compared with $9.4 million in the same period of 2024.
G&A Expenses: G&A expenses were $5.1 million, compared with $5.6 million in the same period of 2024.
Investment Income: Investment income was $117,000, compared with $423,000 in the same period of 2024.

Cash and Cash Equivalents: As of September 30, 2025, cash and cash equivalents were $5.3 million.
Capital Resources: The company received $4.5 million in net proceeds from the exercise of warrants and sales under its ATM facility during the third quarter of 2025.

IMUNON believes it has sufficient capital resources to fund its planned operations into the first quarter of 2026.